<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:sling="http://sling.apache.org/jcr/sling/1.0"
    jcr:primaryType="cq:Page">
    <jcr:content
        cq:lastModified="{Date}2024-02-08T16:36:10.599Z"
        cq:lastModifiedBy="msm-service"
        cq:lastRolledout="{Date}2024-02-08T16:36:10.603Z"
        cq:lastRolledoutBy="msm-service"
        cq:template="/conf/menarini-berlinchemie/settings/wcm/templates/menarini---details-news"
        jcr:mixinTypes="[cq:LiveRelationship]"
        jcr:primaryType="cq:PageContent"
        jcr:title="Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology"
        sling:resourceType="menarinimaster/components/page"
        dnnNewsIdentifier="8a1c191b-1720-40aa-88de-c68d8076ed34-3033">
        <root
            cq:lastRolledout="{Date}2024-02-08T16:36:09.299Z"
            cq:lastRolledoutBy="msm-service"
            jcr:mixinTypes="[cq:LiveRelationship]"
            jcr:primaryType="nt:unstructured"
            sling:resourceType="menarinimaster/components/container"
            layout="responsiveGrid">
            <container
                cq:lastRolledout="{Date}2024-02-08T16:36:09.382Z"
                cq:lastRolledoutBy="msm-service"
                jcr:mixinTypes="[cq:LiveRelationship]"
                jcr:primaryType="nt:unstructured"
                sling:resourceType="menarinimaster/components/container"
                layout="responsiveGrid">
                <internalheader
                    cq:lastRolledout="{Date}2024-02-08T16:36:09.443Z"
                    cq:lastRolledoutBy="msm-service"
                    jcr:mixinTypes="[cq:LiveRelationship]"
                    jcr:primaryType="nt:unstructured"
                    jcr:title="News &amp; Medien"
                    sling:resourceType="menarinimaster/components/internalheader"
                    altValueFromDAM="{Boolean}false"
                    imageFromPageImage="{Boolean}false"
                    titleFromPage="{Boolean}false"/>
                <section
                    cq:lastRolledout="{Date}2024-02-08T16:36:09.451Z"
                    cq:lastRolledoutBy="msm-service"
                    jcr:lastModified="{Date}2024-02-08T16:36:09.445Z"
                    jcr:lastModifiedBy="a.messori@adiacent.com"
                    jcr:mixinTypes="[cq:LiveRelationship]"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/section">
                    <wrapper
                        cq:lastRolledout="{Date}2024-02-08T16:36:09.480Z"
                        cq:lastRolledoutBy="msm-service"
                        jcr:lastModified="{Date}2024-02-08T16:36:09.475Z"
                        jcr:lastModifiedBy="a.messori@adiacent.com"
                        jcr:mixinTypes="[cq:LiveRelationship]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/wrapper">
                        <breadcrumb
                            cq:lastRolledout="{Date}2024-02-08T16:36:09.510Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/breadcrumb"/>
                    </wrapper>
                </section>
                <container
                    cq:lastRolledout="{Date}2024-02-08T16:36:09.561Z"
                    cq:lastRolledoutBy="msm-service"
                    jcr:mixinTypes="[cq:LiveRelationship]"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/container"
                    layout="responsiveGrid">
                    <internalmenu
                        cq:lastRolledout="{Date}2024-02-08T16:36:09.611Z"
                        cq:lastRolledoutBy="msm-service"
                        jcr:mixinTypes="[cq:LiveRelationship]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/internalmenu"
                        navigationRoot="/content/menarini-berlinchemie/en/News-Medien"
                        structureStart="{Long}0">
                        <cq:responsive
                            cq:lastRolledout="{Date}2024-02-08T16:36:09.721Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured">
                            <default
                                cq:lastRolledout="{Date}2024-02-08T16:36:09.805Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="3"/>
                            <tablet
                                cq:lastRolledout="{Date}2024-02-08T16:36:09.811Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="4"/>
                            <phone
                                cq:lastRolledout="{Date}2024-02-08T16:36:09.818Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </internalmenu>
                    <container
                        cq:lastRolledout="{Date}2024-02-08T16:36:09.983Z"
                        cq:lastRolledoutBy="msm-service"
                        cq:styleIds="[1684742346871]"
                        jcr:mixinTypes="[cq:LiveRelationship]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/container"
                        layout="responsiveGrid">
                        <news_data
                            cq:lastRolledout="{Date}2024-02-08T16:36:10.132Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/news_data"
                            newsDate="{Date}2023-11-20T09:44:00.000Z">
                            <cq:responsive
                                cq:lastRolledout="{Date}2024-02-08T16:36:10.161Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured">
                                <default
                                    cq:lastRolledout="{Date}2024-02-08T16:36:10.199Z"
                                    cq:lastRolledoutBy="msm-service"
                                    jcr:mixinTypes="[cq:LiveRelationship]"
                                    jcr:primaryType="nt:unstructured"
                                    offset="0"
                                    width="9"/>
                            </cq:responsive>
                        </news_data>
                        <title
                            cq:lastRolledout="{Date}2024-02-08T16:36:10.208Z"
                            cq:lastRolledoutBy="msm-service"
                            cq:styleIds="[1653552493699]"
                            jcr:lastModified="{Date}2024-02-08T16:36:10.203Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/title"
                            linkTarget="_self"
                            type="h2"/>
                        <image
                            cq:lastRolledout="{Date}2024-02-08T16:36:10.220Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:lastModified="{Date}2024-02-08T16:36:10.213Z"
                            jcr:lastModifiedBy="Importer"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/image"
                            displayPopupTitle="true"
                            fileReference="/content/dam/menarini-berlinchemie/assets/news/Stemline-menarini-800-450-p-L-97-800-450-p-L-97-800-450-p-L-97.jpg"
                            imageFromPageImage="{Boolean}false"
                            isDecorative="true"
                            linkTarget="_self"
                            titleValueFromDAM="false">
                            <cq:responsive
                                cq:lastRolledout="{Date}2024-02-08T16:36:10.314Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured">
                                <default
                                    cq:lastRolledout="{Date}2024-02-08T16:36:10.379Z"
                                    cq:lastRolledoutBy="msm-service"
                                    jcr:mixinTypes="[cq:LiveRelationship]"
                                    jcr:primaryType="nt:unstructured"
                                    offset="2"
                                    width="4"/>
                                <phone
                                    cq:lastRolledout="{Date}2024-02-08T16:36:10.386Z"
                                    cq:lastRolledoutBy="msm-service"
                                    jcr:mixinTypes="[cq:LiveRelationship]"
                                    jcr:primaryType="nt:unstructured"
                                    offset="1"
                                    width="10"/>
                            </cq:responsive>
                        </image>
                        <spacer
                            cq:lastRolledout="{Date}2024-02-08T16:36:10.394Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:lastModified="{Date}2024-02-08T16:36:10.388Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/spacer"
                            spacer="40"/>
                        <text
                            cq:lastRolledout="{Date}2024-02-08T16:36:10.404Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:lastModified="{Date}2024-02-08T16:36:10.397Z"
                            jcr:lastModifiedBy="Importer"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/text"
                            text="&lt;h1>&lt;span style=&quot;background:white&quot;>Annual Meeting and Exposition&lt;/span>&lt;/h1>&#xa;&#xa;&lt;p style=&quot;text-align: center;&quot;>&lt;img alt=&quot;&quot; loading=&quot;lazy&quot; src=&quot;/Portals/31/menarinigroup.jpg&quot; style=&quot;width: 392px; height: 170px;&quot; title=&quot;&quot; />&lt;img alt=&quot;&quot; loading=&quot;lazy&quot; src=&quot;/Portals/31/Stemline.jpg&quot; style=&quot;width: 374px; height: 167px;&quot; title=&quot;&quot; />&lt;/p>&#xa;&#xa;&lt;ul>&#xa; &lt;li style=&quot;border:none; margin-left:8px&quot;>&lt;span style=&quot;background:white&quot;>&lt;i>Data spans eleven presentations across both &lt;span style=&quot;background:white&quot;>solid tumors and hematologic malignancies&lt;/span>, providing added understanding of the potential benefit these therapies bring to patients &lt;/i>&lt;/span>&lt;/li>&#xa; &lt;li style=&quot;border:none; margin-left:8px&quot;>&lt;span style=&quot;background:white&quot;>&lt;i>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>ORSERDU data reinforce its key role in the treatment of ER+, HER2- advanced or metastatic breast cancer (mBC) tumors that harbor ESR1 mutations, while showing initial data from combination trials&amp;nbsp;&lt;/span>&lt;/i>&lt;/span>&lt;/li>&#xa; &lt;li style=&quot;border:none; margin-left:8px&quot;>&lt;span style=&quot;background:white&quot;>&lt;i>ELZONRIS presentation includes updated real-world data from patients with Blastic Plasmacytoid Dendritic Cell Neoplasm&lt;/i>&lt;/span>&lt;/li>&#xa;&lt;/ul>&#xa;&#xa;&lt;p style=&quot;border:none; margin-bottom:10px; margin-left:8px&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p>&lt;b>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>FLORECE, Italy&amp;nbsp;and&amp;nbsp;NEW YORK,&amp;nbsp;Nov. 20, 2023&lt;/span>&lt;/b>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>&amp;nbsp;-- The Menarini Group (&amp;quot;Menarini&amp;quot;), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (&amp;quot;Stemline&amp;quot;), a wholly-owned subsidiary of the Menarini Group &lt;/span>focused on bringing transformational oncology treatments to cancer patients&lt;span style=&quot;background:white&quot;>, announced today that they will present new data related to ORSERDU&amp;reg; (elacestrant) and ELZONRIS&amp;reg; (tagraxofusp-erzs) in two upcoming congresses.&lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>ORSERDU, a once-daily oral endocrine monotherapy, for the treatment of postmenopausal women or adult men, with ER+, HER2-,&amp;nbsp;&lt;i>&lt;span style=&quot;border:none windowtext 1.0pt; padding:0cm&quot;>ESR1&lt;/span>&lt;/i>-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, was approved by the&amp;nbsp;&lt;span style=&quot;border:none windowtext 1.0pt; letter-spacing:.2pt; padding:0cm&quot;>U.S. Food and&amp;nbsp;&lt;/span>&lt;span style=&quot;border:none windowtext 1.0pt; letter-spacing:.3pt; padding:0cm&quot;>Drug&lt;/span>&amp;nbsp;&lt;span style=&quot;border:none windowtext 1.0pt; letter-spacing:.15pt; padding:0cm&quot;>Ad&lt;/span>&lt;/span>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>&lt;span style=&quot;border:none windowtext 1.0pt; letter-spacing:.15pt; padding:0cm&quot;>ministration in&amp;nbsp;&lt;/span>&lt;/span>&lt;a href=&quot;https://www.menarini.com/en-us/news/news-detail/stemline-therapeutics-a-subsidiary-of-menarini-group-receives-us-fda-approval-for-orserdutm-elacestrant-as-the-first-and-only-treatment-specifically-indicated-for-patients-with-esr1-mutations&quot;>&lt;span style=&quot;border:none windowtext 1.0pt; background:white; padding:0cm&quot;>&lt;span style=&quot;letter-spacing:.15pt&quot;>January 2023&lt;/span>&lt;/span>&lt;/a>&lt;span lang=&quot;EN-GB&quot; style=&quot;border:none windowtext 1.0pt; background:white; padding:0cm&quot;>&lt;span style=&quot;letter-spacing:.15pt&quot;>&amp;nbsp;under&amp;nbsp;&lt;/span>&lt;/span>&lt;span lang=&quot;EN-GB&quot; style=&quot;border:none windowtext 1.0pt; background:white; padding:0cm&quot;>&lt;span style=&quot;letter-spacing:.1pt&quot;>its&amp;nbsp;&lt;/span>&lt;/span>&lt;span lang=&quot;EN-GB&quot; style=&quot;border:none windowtext 1.0pt; background:white; padding:0cm&quot;>&lt;span style=&quot;letter-spacing:.15pt&quot;>priority review&amp;nbsp;&lt;/span>&lt;/span>&lt;span lang=&quot;EN-GB&quot; style=&quot;border:none windowtext 1.0pt; background:white; padding:0cm&quot;>&lt;span style=&quot;letter-spacing:.1pt&quot;>and fast&amp;nbsp;&lt;/span>&lt;/span>&lt;span lang=&quot;EN-GB&quot; style=&quot;border:none windowtext 1.0pt; background:white; padding:0cm&quot;>&lt;span style=&quot;letter-spacing:.15pt&quot;>track designation. &amp;nbsp;In&amp;nbsp;&lt;/span>&lt;/span>&lt;a href=&quot;https://www.menarini.com/en-us/news/news-detail/european-commission-approves-menarini-groups-orserdu174-elacestrant-for-the-treatment-of-patients-with-er-her2-locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation&quot;>&lt;span style=&quot;border:none windowtext 1.0pt; background:white; padding:0cm&quot;>&lt;span style=&quot;letter-spacing:.15pt&quot;>September 2023&lt;/span>&lt;/span>&lt;/a>&lt;span lang=&quot;EN-GB&quot; style=&quot;border:none windowtext 1.0pt; background:white; padding:0cm&quot;>&lt;span style=&quot;letter-spacing:.15pt&quot;>, ORSERDU was approved by the European Commission.&lt;s> &lt;/s>&lt;/span>&lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>Updated data, including&amp;nbsp;a&amp;nbsp;spotlight&amp;nbsp;discussion on&amp;nbsp;additional&amp;nbsp;biomarker&amp;nbsp;and&amp;nbsp;clinical subgroup analyses from the Phase 3 EMERALD trial,&amp;nbsp;along with&amp;nbsp;new safety updates evaluating&amp;nbsp;elacestrant&amp;nbsp;in multiple combination&amp;nbsp;settings,&amp;nbsp;will be presented at the San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.&lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>ELZONRIS was approved by the FDA&amp;nbsp;&lt;/span>in &lt;a href=&quot;http://www.elzonris.com&quot;>December 2018&lt;/a>&lt;span style=&quot;background:white&quot;> for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and &lt;/span>pediatric patients two years and older, in both treatment-naïve and previously-treated populations. In &lt;a href=&quot;https://www.menarini.com/en-us/news/news-archive/article-details/menarini-receives-european-commission-approval-of-elzonris-tagraxofusp-for-the-treatment-of-blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn&quot;>January 2021&lt;/a>, &lt;span style=&quot;background:white&quot;>ELZONRIS was approved by the European Commission.&amp;nbsp;&lt;/span>Updated data, including an oral presentation of updated real-world results in treatment-naïve patients with BPDCN demonstrating &lt;w:sdt id=&quot;179248524&quot; sdttag=&quot;goog_rdk_1&quot;>&lt;/w:sdt>&lt;span style=&quot;background:white&quot;>d&lt;/span>urable outcomes and a manageable safety profile leading to prolonged survival,&lt;span style=&quot;background:white&quot;> will be presented at the 65&lt;sup>th&lt;/sup> American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, December 9-12, 2023.&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;border:none&quot;>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>&amp;ldquo;The breadth of data on our novel oncology therapies, spanning solid tumors and hematologic malignancies, underscore our commitment to addressing significant unmet medical needs in difficult-to-treat cancers,&amp;rdquo; said&amp;nbsp;Elcin Barker Ergun, CEO of the Menarini Group. &amp;ldquo;At Menarini Stemline, we are dedicated to driving innovation in oncology&lt;/span> &lt;span style=&quot;background:white&quot;>to deliver targeted therapies that bring value to people living with cancer and to the healthcare providers who care for them.&amp;rdquo;&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;border:none&quot;>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>See below for full details of the &lt;/span>&lt;w:sdt id=&quot;1158338021&quot; sdttag=&quot;goog_rdk_2&quot;>&lt;/w:sdt>&lt;span style=&quot;background:white&quot;>Menarini Group/Stemline Therapeutics&amp;#39; upcoming presentations:&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;border:none&quot;>&lt;br />&#xa;&lt;b>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>San Antonio Breast Cancer Symposium 2023&lt;/span>&lt;/b>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;table class=&quot;Table&quot; style=&quot;border-collapse:collapse; border:none&quot; width=&quot;642&quot;>&#xa; &lt;tbody>&#xa;  &lt;tr>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:75px; padding:0cm 7px 0cm 7px; height:50px; border-top:1px solid black; border-right:1px solid black; border-left:1px solid black&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;b>Lead Author​&lt;/b>&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:453px; padding:0cm 7px 0cm 7px; height:50px; border-top:1px solid black; border-right:1px solid black; border-left:none&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;b>Abstract Title and ID​&lt;/b>&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:114px; padding:0cm 7px 0cm 7px; height:50px; border-top:1px solid black; border-right:1px solid black; border-left:none&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;b>Presentation Details​&lt;/b>&lt;/p>&#xa;   &lt;/td>&#xa;  &lt;/tr>&#xa;  &lt;tr>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:75px; padding:0cm 7px 0cm 7px; height:66px; border-top:none; border-right:1px solid black; border-left:1px solid black&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>Bardia, A​&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:453px; padding:0cm 7px 0cm 7px; height:66px; border-top:none; border-right:1px solid black; border-left:none&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>Elacestrant&amp;nbsp;vs standard-of-care in ER+/HER2- advanced or metastatic breast cancer (mBC) with&amp;nbsp;&lt;i>ESR1&amp;nbsp;&lt;/i>mutation: key&amp;nbsp;biomarkers and clinical subgroup analyses from the phase 3&amp;nbsp;EMERALD trial​&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>1576519/PS17-02&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:114px; padding:0cm 7px 0cm 7px; height:66px; border-top:none; border-right:1px solid black; border-left:none&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>December 8, 2023​&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>7-8am CT&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Poster Spotlight Discussion&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Hemisfair Ballroom 1-2&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;  &lt;/tr>&#xa;  &lt;tr>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:75px; padding:0cm 7px 0cm 7px; height:56px; border-top:none; border-right:1px solid black; border-left:1px solid black&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>Rugo, H​&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:453px; padding:0cm 7px 0cm 7px; height:56px; border-top:none; border-right:1px solid black; border-left:none&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>ELEVATE: A phase 1b/2, open-label, umbrella study evaluating&amp;nbsp;elacestrant&amp;nbsp;in various combinations in patients (pts)&amp;nbsp;with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)​&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>1576517/PO2-05-04&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:114px; padding:0cm 7px 0cm 7px; height:56px; border-top:none; border-right:1px solid black; border-left:none&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>December 6, 2023​&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>5-7pm CT​&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Poster&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Halls 2-3&lt;/p>&#xa;   &lt;/td>&#xa;  &lt;/tr>&#xa;  &lt;tr>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:75px; padding:0cm 7px 0cm 7px; height:49px; border-top:none; border-right:1px solid black; border-left:1px solid black&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>Ibrahim, N​&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:453px; padding:0cm 7px 0cm 7px; height:49px; border-top:none; border-right:1px solid black; border-left:none&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>ELECTRA:&amp;nbsp;An open-label, multicenter, phase 1b/2 study of&amp;nbsp;elacestrant&amp;nbsp;in combination with&amp;nbsp;abemaciclib&amp;nbsp;in patients&amp;nbsp;with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>1576518​/PO2-05-05&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:114px; padding:0cm 7px 0cm 7px; height:49px; border-top:none; border-right:1px solid black; border-left:none&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>December 6, 2023​&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>5-7pm CT​&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Poster&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Halls 2-3&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;  &lt;/tr>&#xa;  &lt;tr>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:75px; padding:0cm 7px 0cm 7px; height:60px; border-top:none; border-right:1px solid black; border-left:1px solid black&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>Patnaik, A​&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:453px; padding:0cm 7px 0cm 7px; height:60px; border-top:none; border-right:1px solid black; border-left:none&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>SUMIT-ELA:&amp;nbsp;Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i)&amp;nbsp;samuraciclib&amp;nbsp;and selective&amp;nbsp;estrogen&amp;nbsp;receptor degrader (SERD)&amp;nbsp;elacestrant&amp;nbsp;in advanced hormone receptor positive (HR+) breast cancer after&amp;nbsp;CDK4/6i*&amp;nbsp;&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>NA/PO3-04-13&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:114px; padding:0cm 7px 0cm 7px; height:60px; border-top:none; border-right:1px solid black; border-left:none&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>December 7, 2023&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>12-2pm CT​&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Poster&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Halls 2-3&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;  &lt;/tr>&#xa;  &lt;tr>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:75px; padding:0cm 7px 0cm 7px; height:52px; border-top:none; border-right:1px solid black; border-left:1px solid black&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>Bellet, M​&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:453px; padding:0cm 7px 0cm 7px; height:52px; border-top:none; border-right:1px solid black; border-left:none&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>A phase 2 randomized pre-operative, window of opportunity trial investigating the effect of&amp;nbsp;elacestrant&amp;nbsp;with/without&amp;nbsp;triptorelin in premenopausal patients with HR+/HER2- breast cancer &amp;ndash;&amp;nbsp;SOLTI-2104-PremiÈRe trial*​&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>1580190/PO3-19-08&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:114px; padding:0cm 7px 0cm 7px; height:52px; border-top:none; border-right:1px solid black; border-left:none&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>December 7, 2023​12-2pm CT​&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Poster&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Halls 2-3&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;  &lt;/tr>&#xa; &lt;/tbody>&#xa;&lt;/table>&#xa;&#xa;&lt;p style=&quot;border:none&quot;>&lt;span style=&quot;background:#fefefe&quot;>&lt;i>*&lt;/i>&lt;i>Denotes investigator sponsored research or collaborative research&lt;/i>&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;border:none&quot;>&lt;b>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>65&lt;sup>th&lt;/sup> American Society of Hematology (ASH) Annual Meeting 2023&lt;/span>&lt;/b>&lt;/p>&#xa;&#xa;&lt;table class=&quot;Table&quot; style=&quot;border-collapse:collapse; border:none&quot; width=&quot;642&quot;>&#xa; &lt;tbody>&#xa;  &lt;tr>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:103px; padding:0cm 7px 0cm 7px; border-top:1px solid black; border-right:1px solid black; border-left:1px solid black&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;b>Lead Author&lt;/b>&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:255px; padding:0cm 7px 0cm 7px; border-top:1px solid black; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;b>Title and Publication Number&lt;/b>&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:151px; padding:0cm 7px 0cm 7px; border-top:1px solid black; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;b>Session Name&lt;/b>&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:132px; padding:0cm 7px 0cm 7px; border-top:1px solid black; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;b>Presentation Details&lt;/b>&lt;/p>&#xa;   &lt;/td>&#xa;  &lt;/tr>&#xa;  &lt;tr>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:103px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:1px solid black&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>Angelucci et al.&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:255px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;a href=&quot;https://ash.confex.com/ash/2023/webprogram/Paper178734.html&quot;>Durable Outcomes with Manageable Safety Leading to Prolonged Survival with Tagraxofusp for Treatment-Naive Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Updated Results from a European Named Patient Program&lt;/a>&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Publication Number: 547&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:151px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>906. Outcomes Research &amp;ndash; Myeloid Malignancies: Real-World Treatment Patterns and Outcomes&lt;br />&#xa;   &amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:132px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;b>Oral &lt;/b>&lt;w:sdt id=&quot;245542736&quot; sdttag=&quot;goog_rdk_3&quot;>&lt;/w:sdt>&lt;b>Presentation&lt;/b>&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>December 10, 2023&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>12:00 PM&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;  &lt;/tr>&#xa;  &lt;tr>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:103px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:1px solid black&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;w:sdt id=&quot;-20163657&quot; sdttag=&quot;goog_rdk_4&quot;>&lt;/w:sdt>Minetto et al.&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:255px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;a href=&quot;https://ash.confex.com/ash/2023/webprogram/Paper189417.html&quot;>Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: An Interim Analysis of Italian GIMEMA AML2020 Trial&lt;/a>&lt;u>*&lt;/u>&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>Publication Number: 2918&lt;/span>&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:151px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II&lt;/span>&lt;br />&#xa;   &amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:132px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;b>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>Poster&lt;/span>&lt;/b>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;> &lt;b>Presentation&lt;/b>&lt;/span>&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>December 10, 2023&lt;/span>&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>6:00 PM - 8:00 PM&lt;br />&#xa;   San Diego Convention Center, Halls G-H&lt;/span>&lt;/p>&#xa;   &lt;/td>&#xa;  &lt;/tr>&#xa;  &lt;tr>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:103px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:1px solid black&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;w:sdt id=&quot;2041624216&quot; sdttag=&quot;goog_rdk_6&quot;>&lt;/w:sdt>Lane et al.&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:255px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;a href=&quot;https://ash.confex.com/ash/2023/webprogram/Paper180010.html&quot;>Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial&lt;/a>&lt;u>*&lt;/u>&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Publication Number: 4277&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:151px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:132px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;b>Poster Presentation&lt;/b>&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>December 11, 2023&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>6:00 PM - 8:00 PM&lt;br />&#xa;   San Diego Convention Center, Halls G-H&amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;  &lt;/tr>&#xa;  &lt;tr>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:103px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:1px solid black&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;w:sdt id=&quot;407969197&quot; sdttag=&quot;goog_rdk_5&quot;>&lt;/w:sdt>Boichut et al.&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:255px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;a href=&quot;https://ash.confex.com/ash/2023/webprogram/Paper186126.html&quot;>Analysis of tagraxofusp activity in AML-PDC as a single agent and in combination with BCL2 inhibitors&lt;/a>&lt;u>*&lt;/u>&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Publication Number: 2783&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:151px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II&lt;br />&#xa;   &amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:132px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;b>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>Poster&lt;/span>&lt;/b>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;> &lt;b>Presentation&lt;/b>&lt;/span>&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>December 10, 2023&lt;br />&#xa;   6:00 PM - 8:00 PM&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>San Diego Convention Center, Halls G-H&lt;/p>&#xa;   &lt;/td>&#xa;  &lt;/tr>&#xa;  &lt;tr>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:103px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:1px solid black&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;w:sdt id=&quot;-806463478&quot; sdttag=&quot;goog_rdk_7&quot;>&lt;/w:sdt>&lt;w:sdt id=&quot;-1154297798&quot; sdttag=&quot;goog_rdk_8&quot;>&lt;/w:sdt>&lt;span style=&quot;background:white&quot;>Navarro Vicente et al.&lt;/span>&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:255px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;w:sdt id=&quot;1865484220&quot; sdttag=&quot;goog_rdk_9&quot;>&lt;/w:sdt>&lt;a href=&quot;https://ash.confex.com/ash/2023/webprogram/Paper190296.html&quot;>&lt;span style=&quot;background:white&quot;>Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)&lt;/span>&lt;/a>&lt;u>&lt;span style=&quot;background:white&quot;>*&lt;/span>&lt;/u>&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>Publication Number: 4234&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:151px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III&lt;br />&#xa;   &amp;nbsp;&lt;/p>&#xa;   &lt;/td>&#xa;   &lt;td style=&quot;border-bottom:1px solid black; width:132px; padding:0cm 7px 0cm 7px; border-top:none; border-right:1px solid black; border-left:none&quot; valign=&quot;top&quot;>&#xa;   &lt;p style=&quot;border:none&quot;>&lt;b>&lt;span lang=&quot;EN-GB&quot; style=&quot;background:white&quot;>Poster Presentation&lt;/span>&lt;/b>&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>December 11, 2023&lt;/p>&#xa;&#xa;   &lt;p style=&quot;border:none&quot;>6:00 PM - 8:00 PM&lt;br />&#xa;   San Diego Convention Center, Halls G-H&lt;/p>&#xa;   &lt;/td>&#xa;  &lt;/tr>&#xa; &lt;/tbody>&#xa;&lt;/table>&#xa;&#xa;&lt;p style=&quot;border:none&quot;>&lt;span style=&quot;background:#fefefe&quot;>&lt;i>*&lt;/i>&lt;i>Denotes investigator sponsored research or collaborative research&lt;/i>&lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&lt;b>About the EMERALD Phase 3 Study (NCT03778931)&lt;/b>&lt;br />&#xa;The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+, HER2- advanced/mBC patients. The study enrolled 478 patients who had received prior treatment with one or two lines of endocrine therapy, including a CDK4/6 inhibitor. Patients in the study were randomized to receive either elacestrant or the investigator&amp;#39;s choice of an approved hormonal agent. The primary endpoints of the study were progression-free survival (PFS) in the overall patient population and in patients with estrogen receptor 1 gene (&lt;i>ESR1&lt;/i>) mutations. In the group of patients whose tumors had&amp;nbsp;&lt;i>ESR1&lt;/i> mutations, elacestrant achieved a median PFS of 3.8 months vs 1.9 months on the SOC, and reduced the risk of progression or death by 45% (PFS HR=0.55, 95% CI: 0.39, 0.77) vs SOC.&lt;/p>&#xa;&#xa;&lt;p>&lt;b>About ORSERDU&amp;reg; (elacestrant)&lt;/b>&lt;br />&#xa;&lt;span style=&quot;background:#fefefe&quot;>&lt;b>U.S. Indication: &lt;/b>ORSERDU (elacestrant), 345 mg tablets, is approved by the U.S. Food &amp;amp; Drug Administration (FDA) for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.&lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&lt;span style=&quot;background:#fefefe&quot;>Full prescribing information for the U.S. can be found at&amp;nbsp;&lt;a href=&quot;http://www.orserdu.com&quot;>www.orserdu.com&lt;/a> &lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&lt;span style=&quot;background:#fefefe&quot;>&lt;b>Important Safety Information, ORSERDU&amp;reg;&lt;/b>&lt;/span>&lt;br />&#xa;&lt;i>Warning and Precautions&lt;br />&#xa;Dyslipidemia&lt;/i>: Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively.&amp;nbsp; Monitor lipid profile prior to starting and periodically while taking ORSERDU.&lt;br />&#xa;&lt;br />&#xa;&lt;i>Embryo-Fetal Toxicity&lt;/i>: Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman.&amp;nbsp; Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the final dose.&lt;/p>&#xa;&#xa;&lt;p>&lt;i>Adverse Reactions&lt;br />&#xa;Serious adverse reactions&lt;/i> occurred in 12% of patients who received ORSERDU. Serious adverse reactions in &amp;gt;1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each).&lt;br />&#xa;&lt;br />&#xa;&lt;i>The most common adverse reactions (&lt;u>&amp;gt;&lt;/u>10%)&lt;/i>, including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite (15%), diarrhea (13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%).&lt;/p>&#xa;&#xa;&lt;p>&lt;i>Drug interactions&lt;br />&#xa;Concomitant use with CYP3A4 Inducers and/or inhibitors&lt;/i>:&amp;nbsp; Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU.&lt;br />&#xa;&lt;br />&#xa;&lt;i>Use in specific populations&lt;br />&#xa;Lactation&lt;/i>: Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose.&lt;br />&#xa;&lt;i>Hepatic Impairment&lt;/i>: Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B).&lt;/p>&#xa;&#xa;&lt;p>The safety and effectiveness of ORSERDU in pediatric patients have not been established.&lt;br />&#xa;&lt;span style=&quot;background:white&quot;>To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at&amp;nbsp;1-877-332-7961 or FDA at&amp;nbsp;1-800-FDA-1088&amp;nbsp;or&amp;nbsp;&lt;a href=&quot;http://www.fda.gov/medwatch&quot;>www.fda.gov/medwatch&lt;/a>. &lt;/span>&lt;/p>&#xa;&#xa;&lt;p>Elacestrant is also being investigated in several clinical trials in metastatic breast cancer disease, alone or in combination with other therapies: ELEVATE (&lt;a href=&quot;https://clinicaltrials.gov/ct2/show/NCT05563220&quot;>NCT05563220&lt;/a>); ELECTRA (&lt;a href=&quot;https://clinicaltrials.gov/ct2/show/NCT05386108&quot;>NCT05386108&lt;/a>); and ELCIN (&lt;a href=&quot;https://clinicaltrials.gov/ct2/show/NCT05596409&quot;>NCT05596409&lt;/a>). Elacestrant is also being evaluated in early breast cancer disease.&lt;/p>&#xa;&#xa;&lt;p>&lt;b>About ELZONRIS&lt;sup>&amp;reg;&lt;/sup>&amp;nbsp;(tagraxofusp-erzs)&lt;/b>&lt;/p>&#xa;&#xa;&lt;p>&lt;b>U.S. Indication: &lt;/b>ELZONRIS (tagraxofusp-erzs) is a prescription medicine used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.&lt;br />&#xa;Full prescribing information for the U.S. can be found at &lt;a href=&quot;http://www.elzonris.com&quot;>www.elzonris.com&lt;/a>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p>&lt;b>IMPORTANT SAFETY INFORMATION, ELZONRIS&amp;reg;&lt;/b>&lt;br />&#xa;&lt;span style=&quot;background:white&quot;>&lt;strong>Boxed WARNING: CAPILLARY LEAK SYNDROME&lt;/strong>&lt;/span>&lt;/p>&#xa;&#xa;&lt;ul>&#xa; &lt;li style=&quot;margin-left:19px&quot;>&lt;span style=&quot;background:white&quot;>&lt;span style=&quot;tab-stops:list 36.0pt&quot;>&lt;strong>Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended.&lt;/strong>&lt;/span>&lt;/span>&lt;/li>&#xa;&lt;/ul>&#xa;&#xa;&lt;h2>&amp;nbsp;&lt;/h2>&#xa;&#xa;&lt;p>&lt;span style=&quot;background:white&quot;>&lt;span style=&quot;font-weight:normal&quot;>&lt;i>Warnings and Precautions&lt;/i>&lt;/span>&lt;/span>&lt;br />&#xa;&lt;span style=&quot;background:white&quot;>&lt;i>Capillary Leak Syndrome&lt;/i>&lt;br />&#xa;Capillary leak syndrome (CLS), including life-threatening and fatal cases, has been reported among patients treated with ELZONRIS. In patients receiving ELZONRIS in clinical trials, the overall incidence of CLS was 53% (65/122), including Grade 1 or 2 in 43% (52/122) of patients, Grade 3 in 7% (8/122) of patients, Grade 4 in 1% (1/122) of patients, and four fatalities (3%). The median time to onset was 4 days (range - 1 to 46 days), and all but 5 patients experienced an event in Cycle 1.&lt;br />&#xa;&lt;br />&#xa;Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is greater than or equal to 3.2 g/dL. During treatment with ELZONRIS, monitor serum albumin levels prior to the initiation of each dose of ELZONRIS and as indicated clinically thereafter, and assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema, including pulmonary edema, hypotension or hemodynamic instability.&lt;/span>&lt;br />&#xa;&lt;br />&#xa;&lt;span style=&quot;background:white&quot;>&lt;i>Hypersensitivity Reactions&lt;/i>&lt;br />&#xa;ELZONRIS can cause severe hypersensitivity reactions. In patients receiving ELZONRIS in clinical trials, hypersensitivity reactions were reported in 43% (53/122) of patients treated with ELZONRIS and were Grade &amp;ge; 3 in 7% (9/122). Manifestations of hypersensitivity reported in&amp;nbsp;&amp;ge; 5%&amp;nbsp;of patients include rash, pruritus, and stomatitis. Monitor patients for hypersensitivity reactions during treatment with ELZONRIS. Interrupt ELZONRIS infusion and provide supportive care as needed if a hypersensitivity reaction should occur.&lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&lt;span style=&quot;background:white&quot;>&lt;i>Hepatotoxicity&lt;/i>&lt;/span>&lt;br />&#xa;Treatment with ELZONRIS was associated with elevations in liver enzymes. In patients receiving ELZONRIS in clinical trials, elevations in ALT occurred in 79% (96/122) and elevations in AST occurred in 76% (93/122). Grade 3 ALT elevations were reported in 26% (32/122) of patients. Grade 3 AST elevations were reported in 30% (36/122) and Grade 4&amp;nbsp;&lt;span style=&quot;background:white&quot;>AST elevations were reported in 3% (4/122) of patients. Elevated liver enzymes occurred in the majority of patients in Cycle 1 and were reversible following dose interruption.&lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&lt;span style=&quot;background:white&quot;>Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with ELZONRIS. Withhold ELZONRIS temporarily if the transaminases rise to greater than 5 times the upper limit of normal and resume treatment upon normalization or when resolved.&lt;/span>&lt;br />&#xa;&lt;br />&#xa;&lt;span style=&quot;background:white&quot;>&lt;span style=&quot;font-weight:normal&quot;>&lt;i>Adverse Reactions&lt;/i>&lt;/span>&lt;br />&#xa;Most common adverse reactions (incidence&amp;nbsp;&amp;ge; 30%) are capillary leak syndrome, nausea, fatigue, pyrexia, peripheral edema, and weight increase. Most common laboratory abnormalities (incidence &amp;ge; 50%) are decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST.&lt;/span>&lt;/p>&#xa;&#xa;&lt;p class=&quot;elzfullpidlmaterials&quot;>&lt;span style=&quot;background:white&quot;>&lt;strong>Please see full&amp;nbsp;&lt;/strong>&lt;a href=&quot;http://pi.elzonris.com/&quot; target=&quot;_blank&quot;>&lt;b>Prescribing Information&lt;/b>&lt;/a>&lt;strong>, including Boxed WARNING.&lt;/strong>&lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&lt;span style=&quot;background:white&quot;>To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at&amp;nbsp;&lt;a href=&quot;tel:18773327961&quot;>1-877-332-7961&lt;/a>&amp;nbsp;or contact the FDA at&amp;nbsp;&lt;a href=&quot;tel:18003321088&quot;>1-800-FDA-1088&lt;/a>&amp;nbsp;or&amp;nbsp;&lt;a href=&quot;https://www.fda.gov/medwatch&quot; target=&quot;_blank&quot;>www.fda.gov/medwatch&lt;/a>.&lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&lt;b>About The Menarini Group&lt;/b>&lt;br />&#xa;The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4.4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini&amp;rsquo;s products are available in 140 countries worldwide. For further information, please visit&amp;nbsp;&lt;a href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.menarini.com&amp;amp;esheet=53558844&amp;amp;newsitemid=20230920907427&amp;amp;lan=en-US&amp;amp;anchor=www.menarini.com&amp;amp;index=5&amp;amp;md5=7682feaaefe280a649c9a9d8a9e54a2c&quot;>www.menarini.com&lt;/a>.&lt;br />&#xa;&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p>&lt;b>About Stemline Therapeutics Inc.&lt;/b>&lt;br />&#xa;Stemline Therapeutics, Inc. (&amp;ldquo;Stemline&amp;rdquo;) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes ORSERDU&amp;reg; (elacestrant) in the U.S. and E.U., an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. &lt;span style=&quot;background:white&quot;>Stemline also commercializes ELZONRIS&amp;reg; (tagraxofusp-erzs), a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States and Europe, which is the only approved treatment for BPDCN in the U.S. and E.U. to date.&amp;nbsp;&lt;/span>Stemline also commercializes NEXPOVIO&amp;reg; (selinexor) in Europe, an XPO1 inhibitor for multiple myeloma. Stemline also has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers.&lt;br />&#xa;&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p>&lt;b>Media Contacts&lt;/b>&lt;/p>&#xa;&#xa;&lt;p>The Menarini Group&lt;br />&#xa;Valeria Speroni Cardi&lt;br />&#xa;Email: pressoffice@menarini.com&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p>Stemline Therapeutics, Inc.&lt;br />&#xa;Cheya Pope&lt;br />&#xa;Email: cpope@menarinistemline.com&lt;/p>&#xa;&#xa;&lt;p>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p>&amp;nbsp;&lt;/p>"
                            textIsRich="true"/>
                        <cq:responsive
                            cq:lastRolledout="{Date}2024-02-08T16:36:10.495Z"
                            cq:lastRolledoutBy="msm-service"
                            jcr:mixinTypes="[cq:LiveRelationship]"
                            jcr:primaryType="nt:unstructured">
                            <default
                                cq:lastRolledout="{Date}2024-02-08T16:36:10.582Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <tablet
                                cq:lastRolledout="{Date}2024-02-08T16:36:10.589Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <phone
                                cq:lastRolledout="{Date}2024-02-08T16:36:10.596Z"
                                cq:lastRolledoutBy="msm-service"
                                jcr:mixinTypes="[cq:LiveRelationship]"
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </container>
                </container>
            </container>
        </root>
        <cq:featuredimage
            cq:lastRolledout="{Date}2024-02-08T16:36:10.602Z"
            cq:lastRolledoutBy="msm-service"
            jcr:mixinTypes="[cq:LiveRelationship]"
            jcr:primaryType="nt:unstructured"
            sling:resourceType="core/wcm/components/image/v3/image"
            altValueFromDAM="{Boolean}false"
            fileReference="/content/dam/menarini-berlinchemie/assets/news/Stemline-menarini-800-450-p-L-97-800-450-p-L-97-800-450-p-L-97.jpg"/>
    </jcr:content>
</jcr:root>
